ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1600527
This article is part of the Research TopicRoles of Hormones in Inflammation and Cancer Progression: New Discoveries and Therapeutic StrategiesView all articles
Integrated Multi-Omics Profiling to Establish an IGFBP-Based Prognostic Score for Pancreatic Ductal Adenocarcinoma: Unraveling Prognostic Biomarkers, Immune Microenvironment Crosstalk, and Therapeutic Implications
Provisionally accepted
- Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, Beijing Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pancreatic ductal adenocarcinoma (PDAC) patients frequently exhibit endocrine dysregulation, particularly aberrations within the insulin and insulin-like growth factor (IGF) signaling systems. Notably, hyperglycemia and insulin resistance are common clinical manifestations in these patients, often paralleled by altered expression levels of the IGF-binding protein (IGFBP) family genes. However, the mechanistic role of IGFBP members in modulating carcinogenesis of PDAC remains elusive. To determine the biological influence of the IGFBP family on PDAC development, we performed a multi-dimensional analysis stratifying established pancreatic cancer cohorts based on IGFBP family expression profiles, subsequently developing a robust prognostic model for PDAC that effectively stratified patients into distinct risk categories. Leveraging singlecell transcriptomic sequencing and spatial transcriptomic profiling, we systematically dissected the functional interplay between IGFBP signaling and the tumor immune microenvironment. In this work, the therapeutic potential of IGFBP family members as molecular targets or prognostic indicators in PDAC is evaluated.
Keywords: Pancreatic Ductal Adenocarcinoma, IGFBP, prognosis, Multi-omics analysis, Tumor Microenvironment
Received: 26 Mar 2025; Accepted: 24 Apr 2025.
Copyright: © 2025 Mu, Guan, Jin and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chengfeng Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, 100006, Beijing Municipality, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.